Skip to main content

SILVERARC CAPITAL MANAGEMENT, LLC

Position in KALV — KalVista Pharmaceuticals, Inc.

CIK 1816307 BOSTON, MA

Position in KALV

as of Mar 31, 2026 · filed May 14, 2026
Position Value
$57,902,072
+$18,704,117 QoQ
Shares Held
2,876,407
+18.5% QoQ
Ownership
5.40%
of shares outstanding
% of Portfolio
6.84%
of 13F equity value
Holder Rank
#6
of 182 holders
Holding Since
Mar 2021
15 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in KALV Over Time

Shares Held

Position Value (USD)

Derivatives in KALV

reported options exposure · as of Dec 31, 2023
CallValue
$2,209,900
CallShares
180,400
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

SILVERARC CAPITAL MANAGEMENT, LLC holds $782,503,784 across 55 Biotechnology names. KALV ranks #1 (7.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 KALV
KalVista Pharmaceuticals, Inc.
This page
2,876,407 $57,902,072

All Filings in KALV

Export CSV
17 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $57,902,072 2,876,407
2025-12-31 $39,197,955 2,427,118
2025-09-30 $16,605,944 1,363,378
2025-06-30 $20,712,693 1,832,171
2025-03-31 $19,606,275 1,698,984
2024-12-31 $5,185,105 612,173
2024-09-30 $6,653,381 574,558
2024-06-30 $6,607,201 560,883
2024-03-31 $6,655,630 561,183
2023-12-31 $2,209,900 180,400
2023-12-31 $1,368,741 111,734
2023-09-30 $5,107,752 530,400
2023-09-30 $2,204,634 228,934
2023-06-30 $6,484,572 720,508
2023-03-31 $5,687,055 723,544
2021-06-30 $356,572 14,882
2021-03-31 $1,284,500 50,000